Inozyme Pharma 관리

관리 기준 확인 2/4

Inozyme Pharma CEO는 Doug Treco, Apr2023 에 임명되었습니다 의 임기는 1.58 년입니다. 총 연간 보상은 $ 5.30M, 7.1% 로 구성됩니다. 7.1% 급여 및 92.9% 보너스(회사 주식 및 옵션 포함). 는 $ 62.87K 가치에 해당하는 회사 주식의 0.035% 직접 소유합니다. 62.87K. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 6.6 년입니다.

주요 정보

Doug Treco

최고 경영자

US$5.3m

총 보상

CEO 급여 비율	7.1%
CEO 임기	1.6yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	6.6yrs

최근 관리 업데이트

Recent updates

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Jul 19

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Jul 12

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Apr 06

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Dec 22

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Sep 08

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

May 22

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

May 07

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Feb 06

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Jan 04

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Dec 03

Inozyme Pharma EPS misses by $1.02

Nov 12

CEO 보상 분석

Doug Treco 의 보수는 Inozyme Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$96m
Jun 30 2024	n/a	n/a	-US$89m
Mar 31 2024	n/a	n/a	-US$77m
Dec 31 2023	US$5m	US$375k	-US$71m
Sep 30 2023	n/a	n/a	-US$68m
Jun 30 2023	n/a	n/a	-US$68m
Mar 31 2023	n/a	n/a	-US$68m
Dec 31 2022	US$106k	n/a	-US$67m
Sep 30 2022	n/a	n/a	-US$67m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$62m
Dec 31 2021	US$188k	n/a	-US$57m
Sep 30 2021	n/a	n/a	-US$49m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$339k	n/a	-US$56m

보상 대 시장: Doug 의 총 보상 ($USD 5.30M )은 US 시장( $USD 1.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Doug 의 보상이 증가했습니다.

CEO

Doug Treco (66 yo)

1.6yrs

테뉴어

US$5,299,476

보상

Dr. Douglas A. Treco, also known as Doug, Ph D., is an Advisor at LSV Capital Management LLC. Earlier he was a Scientific Advisor at the firm.He was Chief Executive Officer of Alchemab Therapeutics from A...

리더십 팀

이름	위치	테뉴어	보상	소유권
Douglas Treco	CEO & Chairman	1.6yrs	US$5.30m	0.035% $ 62.9k
Axel Bolte	Co-Founder	no data	US$1.80m	0.42% $ 749.4k
Sanjay Subramanian	Senior VP	2.7yrs	US$1.03m	0.047% $ 85.4k
Matthew Winton	Senior VP & COO	1.6yrs	US$1.55m	0.0076% $ 13.8k
Demetrios Braddock	Co-Founder	no data	데이터 없음	데이터 없음
Soojin Kim	Senior VP & Chief Technical Operations Officer	2.7yrs	데이터 없음	데이터 없음
David Thompson	Senior VP	1.8yrs	데이터 없음	데이터 없음
Stefan Riley	Director of Investor Relations	no data	데이터 없음	데이터 없음
Gayle Gironda	Senior VP & Chief People Officer	3.3yrs	데이터 없음	데이터 없음
Yves Sabbagh	Chairman of Scientific Advisory Board & Senior VP	no data	데이터 없음	데이터 없음
Stephen J. Palma	Consultant	2.7yrs	데이터 없음	데이터 없음
Kurt Gunter	Senior VP & Chief Medical Officer	2.4yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 관리: INZY 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Douglas Treco	CEO & Chairman	4.5yrs	US$5.30m	0.035% $ 62.9k
Axel Bolte	Co-Founder	9.2yrs	US$1.80m	0.42% $ 749.4k
Demetrios Braddock	Co-Founder	no data	데이터 없음	데이터 없음
Yves Sabbagh	Chairman of Scientific Advisory Board & Senior VP	no data	데이터 없음	데이터 없음
Martin Edwards	Independent Director	7.2yrs	US$129.65k	0% $ 0
Reinaldo Diaz	Lead independent director	7.8yrs	US$130.27k	0% $ 0
Joseph Schlessinger	Member of Scientific Advisory Board	no data	US$135.00k	데이터 없음
Edward Mathers	Independent Director	7.8yrs	US$116.15k	0% $ 0
Robert Hopfner	Independent Director	6yrs	US$112.15k	0% $ 0
Sarah Bhagat	Independent Director	5.7yrs	US$114.65k	0% $ 0
Lynne Sullivan	Independent Director	4.5yrs	US$122.15k	0% $ 0
Michael Levine	Chairperson of Clinical Advisory Board	no data	데이터 없음	데이터 없음

6.6yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: INZY 의 이사회는 경험(평균 재직 기간 6.6 년)으로 간주됩니다.

Inozyme Pharma 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Inozyme Pharma, Inc. Announces Appointment of Erik Harris to its Board of Directors

Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024

CEO & Chairman exercised options and sold US$52k worth of stock

Insufficient new directors

Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer

Inozyme Pharma, Inc. Announces Management Changes

Recent updates

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc. Announces Positive Interim Data from Phase 1 Seaport 1 Trial of INZ-701

Inozyme Pharma, Inc. Announces Appointment of Erik Harris to its Board of Directors

New major risk - Financial position

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

New major risk - Revenue and earnings growth

Price target decreased by 7.5% to US$19.43

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency (PXE) and ENPP1 Deficiency

CEO & Chairman exercised options and sold US$52k worth of stock

New minor risk - Share price stability

Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency

New major risk - Revenue and earnings growth

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions

Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

New minor risk - Share price stability

Price target decreased by 9.3% to US$20.50

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Price target increased by 8.5% to US$22.60

Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701

Insufficient new directors

Price target decreased by 13% to US$19.17

Inozyme Pharma, Inc. Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

Price target increased by 8.5% to US$21.80

Inozyme Pharma, Inc. Provides Business Updates

Inozyme Pharma, Inc. Announces First Self-Administration of Inz-701 in Ongoing Enpp1 Deficiency Phase 1/2 Clinical Trial

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

Price target increased to US$23.20

Inozyme Pharma GAAP EPS of -$0.38

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Index

Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer

Price target decreased to US$29.40

Inozyme Pharma, Inc. Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Price target decreased to US$30.00

Inozyme Pharma, Inc. Announces Management Changes

High number of new directors

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Price target decreased to US$32.25

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Growth Index

President exercised options and sold US$65k worth of stock

Inozyme Pharma, Inc. Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of Inz-701 in Abcc6 Deficiency

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Senior Vice President of Finance Stephen Basso has left the company

Inozyme Pharma, Inc. Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company

New 90-day low: US$19.96

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Inozyme Pharma Announces Executive Changes

Senior VP & Chief Medical Officer has left the company